Abstract
The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials). Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Anti-HIV Agents / therapeutic use*
-
CD4 Lymphocyte Count
-
Didanosine / therapeutic use*
-
Drug Therapy, Combination
-
Enfuvirtide
-
HIV Envelope Protein gp41 / therapeutic use
-
HIV Infections / drug therapy*
-
HIV Infections / immunology*
-
Humans
-
Organophosphonates / therapeutic use*
-
Peptide Fragments / therapeutic use
-
Tenofovir
-
Time Factors
-
Viral Load
Substances
-
Anti-HIV Agents
-
HIV Envelope Protein gp41
-
Organophosphonates
-
Peptide Fragments
-
Enfuvirtide
-
Tenofovir
-
Adenine
-
Didanosine